LIB Therapeutics, LLC

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

Biotechs have faced challenges in the last couple years on many aspects: achieving clinical and regulatory milestones, appeasing investors whom are less willing to take risks on early-stage assets, an

Since its founding in 2020, Chinese firm Hasten Biopharmaceutic Co., Ltd. has doubled down on the growing cardiovascular market in the greater China region. In September, the Hefei, Anhui-headquarte

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Hasten Gets Greater China Rights T